Skip to main content

Table 3 Pharmacokinetic parameters for vortioxetine in a Chinese population and previous pooled non-Chinese analyses

From: Pharmacokinetics and Safety of Vortioxetine in the Chinese Population

Parameter Pooled healthy subjects [22]
(N = 887a)
Pooled MDD/GAD patients [23]
(N = 3183b)
Chinese population (N = 186) [% RSE]
Absorption rate constant (ka), L/h 0.14 0.14 (fixed) 0.14 [6.9]
Volume of distribution, central compartment (V2/F), L 2.0 × 103 3.4 × 103 2.0 × 103 [4.4]
Oral clearance (CL/F), L/h 33 39 31 [5]
\(\varpi^2_{{\text{ka}}}\) c 0.26 0.24 [22]
\(\varpi^2_{\text{V2}}\) d 0.094 0.95 0.11 [25]
\(\varpi^2_{\text{CL}}\) e 0.18 0.78 0.44 [13]
σ 2, f 0.065 0.28 0.091 [19]
AUC24g, ng × h/mL (± SD) 326 ± 202 384 ± 222
Cmaxg, ng/mL (± SD) 14.4 ± 8.5 17.2 ± 11.9
Mean elimination half-life, t1/2
L/h
65.8 ± 26.8 79.8 ± 26.8
  1. ϖ population variance, σ common variance, AUC24 area under the plasma concentration–time curve from time zero to 24 h, CL/F oral clearance, Cmax maximum concentration, GAD generalized anxiety disorder, ka absorption rate constant, RSE relative standard error, SD standard deviation, V2/F volume of distribution, central compartment
  2. a74% non-Chinese
  3. b84% non-Chinese
  4. cInterindividual variance for ka
  5. dInterindividual variance for V2/F
  6. eInterindividual variance for CL/F
  7. fResidual error variance
  8. gSimulated steady-state values for 10 mg (mean ± SD)